

Datasheet



Mouse mAb to **Alpha fetoprotein (AFP)**
Clone **C3**
Isotype **IgG2a-κ**

Source

A BALB/c mouse was immunized with alpha fetoprotein isolated from serum of hepatoma patients.
Fusion partner: Sp2/0.

Specifications

C3 has been characterized in the ISOBM TD-2 workshop and assigned by K. Nunstad to a group of antibodies with low affinity to human alpha fetoprotein. Human alpha fetoprotein is an oncofetal protein of 70 kDa and expressed in fetal liver but normally absent in healthy adult tissues. It is expressed in all yolk sac tumors, in some other germ cell tumors and in hepatocellular carcinomas.




Figure 1: Fetal liver stained with C3 (paraffin)

Species reactivity

Positive: dog, human, monkey, pig.
Negative: cow, mouse, rat.

Applications

C3 is excellent for IHC. In paraffin sections a citrate antigen retrieval step is advised. It can also be used in ELISA, however, the TD-2 workshop found C3 less suitable for an AFP tumor marker test.

| ELISA | Flow cytometry | Frozen sections | Immunofluorescence | Paraffin sections |
|-------|----------------|-----------------|--------------------|-------------------|
| + | + | + | + | Citrate |

Format

Produced in tissue culture contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.

Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

Dilution advice

- ELISA (solid phase: 0,1-100 µg/ml; tracer: 0,001-100 µg/ml for 30 min at RT).
- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunofluorescence (0,5-1,0 µg/ml).
- Immunohistology (formalin-fixed: 1-2 µg/ml for 30 min at RT: staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6,0, for 10-20 min followed by cooling at RT for 20 minutes).

Positive control

Hep-G2 cells, fetal liver or hepatocellular carcinoma.

Datasheet



References

- Tsung K., et al. *J. Immunol. Methods* **39**: 363-368 (1980).
- Michell B. et al. *Eur. J. Cancer Clin. Oncol.* **19**: 1239-1246 (1983).
- Yazova A.K. et al. *Immunol. Lett.* **25**: 325-330 (1990).
- Nustad K. Et al. *Tumor Biol* **19**: 293 -300 (1998).
- Yakimenko E.F. et al. *Tumor Biol* **19**: 301-309 (1998).